ArticleMedicine2026
Relationship between 25-hydroxyvitamin D by liquid chromatography-tandem mass spectrometry and retinopathy in type 2 diabetes mellitus.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigates the relationship between 25-hydroxyvitamin D (25(OH)D) levels and diabetic retinopathy (DR) in patients with type 2 diabetes mellitus (T2DM). Participants were divided into 3 groups based on their 25(OH)D status: normal (group A), insufficient (group B), and deficient (group C). The study analyzed the relationship between 25(OH)D and DR, as well as its association with various clinical parameters. In T2DM patients, 25(OH)D levels were significantly correlated with serum phosphorus (P), serum calcium (Ca), aspartate aminotransferase (AST), hemoglobin A1c (HbA1c), parathyroid hormone (PTH), diabetic peripheral neuropathy (DPN), and DR (all P <.05). Comparison between the DR and non-DR (NDR) groups revealed significant differences in disease duration, triglyceride (TG), blood urea nitrogen, serum creatinine (Scr), urine microalbumin (UMA), urinary creatinine (Ucr), free triiodothyronine (FT3), 25(OH)D3, total 25(OH)D, DPN, diabetic kidney disease, and hypertension (P <.05). Among these, 25(OH)D3, total 25(OH)D, and FT3 were identified as potential risk factors for Dr Vitamin D deficiency was significantly associated with an increased risk of diabetic microvascular complications, including DR, DPN, and diabetic kidney disease (P <.05). Receiver operating characteristic curve analysis indicated that the optimal cutoff values for predicting DR onset in T2DM patients were 23.15 ng/mL for 25(OH)D3 and 23.33 ng/mL for total 25(OH)D. Reduced 25(OH)D levels are closely associated with the development of DR in T2DM patients, with 25(OH)D serving as a protective factor. Given that vitamin D deficiency may elevate the risk of diabetic microvascular complications, routine assessment of vitamin D, particularly vitamin D3, is recommended in the management of T2DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.